Formulary Watch Newsletter

To view this email as a web page, click here.

Pharma makers, PBMs lower insulin prices

While pharmacy benefit managers were grilled about insulin prices at Congressional hearings last week, some PBMs, insurers and pharma makers are already lowering insulin costs.

PBM rebate solutions flawed, study says

While PBMs’ use of rebates has contributed to high drug prices in some cases, proposed solutions for rebates will not reduce overall drug spending, a new study said.

Five myths about biosimilars - and the facts

From our sister brand, Managed Healthcare Executive: Here are five falsehoods being spread about biosimilars that don’t match up with reality.

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.